Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.

Publication Type:

Journal Article

Authors:

Curlin, Marcel E; Cassis-Ghavami, Farah; Magaret, Amalia S; Spies, A Gregory; Duerr, Ann; Celum, Connie L; Sanchez, Jorge L; Margolick, Joseph B; Detels, Roger; McElrath, M Juliana; Corey, Lawrence

Source:

AIDS (London, England), Volume 25, Issue 2, p.153-8 (2011)

Keywords:

2011, Adenoviridae Infections, Adenoviruses, Human, Adult, Africa, AIDS Vaccines, Antibodies, Neutralizing, Case-Control Studies, Female, Genetic Vectors, HIV Seropositivity, HIV-1, Humans, Male, Risk Assessment, South America, United States, Vaccine and Infectious Disease Division

Abstract:

adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition.